SOCIETAL COSTS ASSOCIATED WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE UNITED STATES
SOCIETAL COSTS ASSOCIATED WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE UNITED STATES
复制标题
DOI：
10.1097/iae.0000000000000717
复制
发表时间：
2016-02-01
影响因子：
3.3
通讯作者：
Colman, Shoshana
中科院分区：
文献类型：
--
作者：
Brown, Melissa M.;Brown, Gary C.;Colman, Shoshana
目的：本研究的目的是使用一个横截面的患病率为基础的医疗保健经济调查，以确定每年，增量，眼科社会成本与新生血管性年龄相关性黄斑变性。方法：连续性患者（n = 200）与新生血管性年龄相关性黄斑变性进行了研究。对照队列包括视力良好（20/20-20/25）的患者，而研究队列视力水平包括子队列1：20/30至20/50，子队列2：20/60至20/100，子队列3：20/200至20/400，子队列4：20/800至无光感。一项由访谈者管理的标准化书面调查评估了1）直接眼科医疗费用，2）直接非眼科医疗费用，3）直接非医疗费用，4）仅因新生血管性年龄相关性黄斑degeneration.Results而产生的间接医疗费用：对照组的平均年社会成本为6，116美元，研究组的平均年社会成本为39，910美元（P < 0.001）。研究子队列1的平均成本为20，339美元，而子队列4的平均成本为82，984美元。直接眼科医疗费用占研究队列社会眼科费用的17.9%，而对照队列社会眼科费用为74.1%（P < 0.001），20/800至无光感子队列费用为10.4%。直接非医疗成本，主要是护理人员，包括研究队列社会眼科成本的67.1%，与对照队列成本的21.3%（1，302美元/6，116美元）（P < 0.001）和20/800至无光感子队列costs.Conclusion的74.1%：与新生血管性年龄相关性黄斑变性相关的社会眼科总成本显着增加视力较好的眼睛视力下降。
Purpose:The purpose of this study was to use a cross-sectional prevalence-based health care economic survey to ascertain the annual, incremental, societal ophthalmic costs associated with neovascular age-related macular degeneration.Methods:Consecutive patients (n = 200) with neovascular age-related macular degeneration were studied. A Control Cohort included patients with good (20/20-20/25) vision, while Study Cohort vision levels included Subcohort 1: 20/30 to 20/50, Subcohort 2: 20/60 to 20/100, Subcohort 3: 20/200 to 20/400, and Subcohort 4: 20/800 to no light perception. An interviewer-administered, standardized, written survey assessed 1) direct ophthalmic medical, 2) direct nonophthalmic medical, 3) direct nonmedical, and 4) indirect medical costs accrued due solely to neovascular age-related macular degeneration.Results:The mean annual societal cost for the Control Cohort was $6,116 and for the Study Cohort averaged $39,910 (P < 0.001). Study Subcohort 1 costs averaged $20,339, while Subcohort 4 costs averaged $82,984. Direct ophthalmic medical costs comprised 17.9% of Study Cohort societal ophthalmic costs, versus 74.1% of Control Cohort societal ophthalmic costs (P < 0.001) and 10.4% of 20/800 to no light perception subcohort costs. Direct nonmedical costs, primarily caregiver, comprised 67.1% of Study Cohort societal ophthalmic costs, versus 21.3% ($1,302/$6,116) of Control Cohort costs (P < 0.001) and 74.1% of 20/800 to no light perception subcohort costs.Conclusion:Total societal ophthalmic costs associated with neovascular age-related macular degeneration dramatically increase as vision in the better-seeing eye decreases.